title: Circumcision and complications in patients with haemophilia in southern part of Turkey: Çukurova experience.
abstract: Circumcision is the oldest and most frequent surgical procedure in the world and especially in Turkey as is seen in the other Islamic countries because of religious and traditional pressures. In this study, we aim to report the experience of circumcision at Çukurova University in a total of 76 patients with haemophilia between 1990 and 2011. We retrospectively reviewed medical records of 69 haemophilia patients without inhibitors and seven haemophilia patients with inhibitors who had been circumcised. Before the year 2000, factor concentrates were given before and after circumcision for 6-7 days. After 2000, we used fibrin glue together with factor concentrates for only 3 days. By-passing agents were used for circumcision in haemophilia patients with inhibitors. Twelve of 69 patients without inhibitors were referred to our centre with bleeding after the circumcision before diagnosis of haemophilia. Nine of these twelve patients had severe life threatening bleeding and three of them had moderate bleeding. Sixty-four patients with haemophilia were circumcised in our centre under general anaesthesia except for three patients who were given local anaesthesia. Thirteen of 57 haemophilia patients (22.8%) without inhibitors had seven mild and six moderate bleeding complications. A few patients had significant bleeding, despite adequate factor replacement. Five of seven haemophilia patients with inhibitors had two moderate and three mild bleeding complications. Our experience showed that circumcision for patients with haemophilia should be carefully performed by surgeons together with paediatric haematologist, under appropriate conditions in haemophilia centres which has comprehensive coagulation lab.
authors.affiliation: Department of Pediatric Hematology, Medical Faculty, Cukurova University, Adana, Turkey. ilgen@cu.edu.tr
authors.forename: I
authors.initials: I
authors.lastname: Sasmaz
authors.forename: B
authors.initials: B
authors.lastname: Antmen
authors.forename: G
authors.initials: G
authors.lastname: Leblebisatan
authors.forename: B
authors.initials: B
authors.lastname: Şahin Karagün
authors.forename: Y
authors.initials: Y
authors.lastname: Kilinç
authors.forename: R
authors.initials: R
authors.lastname: Tuncer
mesh_terms: D000293:Adolescent; D001779:Blood Coagulation Factors / Q000008:administration & dosage*; D016063:Blood Loss, Surgical / Q000517:prevention & control*; D002648:Child; D002675:Child, Preschool; D002944:Circumcision, Male / Q000009:adverse effects / Q000379:methods*; D015942:Factor VIIa / Q000008:administration & dosage; D015718:Fibrin Tissue Adhesive / Q000627:therapeutic use; D006467:Hemophilia A / Q000150:complications* / Q000188:drug therapy; D002836:Hemophilia B / Q000150:complications* / Q000188:drug therapy; D006490:Hemostatics / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D008297:Male; D011994:Recombinant Proteins / Q000008:administration & dosage; D012189:Retrospective Studies; D014421:Turkey
chemical_list: D001779:Blood Coagulation Factors; D015718:Fibrin Tissue Adhesive; D006490:Hemostatics; D011994:Recombinant Proteins; C025667:prothrombin complex concentrates; C103587:recombinant FVIIa; D015942:Factor VIIa